BAD NEWS: First-quarter sales and net income for Merck & Co. both plunged — 9 percent and 8 percent, respectively — as the world’s third-largest drugmaker got slammed by generic competition to multiple drugs. It cut its earnings forecast, sending shares down 3 percent in unusually heavy trading.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.